(1 - 29 from 33
)
FDA decision on Opdivo/Yervoy in liver cancer due next March -
pharmaphorum.com
Nov 12, — BMS' head of gastrointestinal cancers Dr Ian Waxman said that HCC “remains a difficult-to-treat cancer and patients are in need of ... › news › fda-decision-on-o...
BMS scores FDA priority review for Opdivo/Yervoy combo in ...www.pmlive.com › pharma_news › bms_scores_fda_pr...
www.pmlive.com
... is the fastest rising cause of cancer-related death,” said Ian Waxman, development lead, gastrointestinal cancers, Bristol-Myers Squibb.
FDA greenlights review of Bristol-Myers Squibb's Opdivo for ...patientdaily.com › stories › fda-greenlights...
patientdaily.com
Dr. Ian Waxman, development lead of Bristol-Myers Squibb's gastrointestinal cancer division, said FDA's decision as a boon for early detection ...
sorted by relevance / date